Cell Banking Outsourcing Market Size to Surpass USD 35,593.6 Mn by 2030

According to the global Cell Banking Outsourcing market size was estimated at USD 9,869.5 million in 2021 and is expected to surpass around USD 35,593.6 million by 2030 and poised to grow at a compound annual growth rate (CAGR) of 16.40% during the forecast period 2022 to 2030.

Get the Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/6794

Key Takeaways:

• By Type, the U.S. Cell Banking Outsourcing market was valued at USD 1.9 million in 2021 and expected to witness growth at a CAGR of 14.7% from 2022 to 2030.
• Master cell banking accounted for the largest market share in 2021owing to rise in these facilities across the globe. Moreover, master cell banks are useful for the preparation of working cell banks and thus find applicability in various research and development perspectives for gene therapy thereby resulting to segment growth
• Stem cells accounted for the largest share with respect to revenue. Increase in research and development activities associated with the applications of stem cells drives the segment growth
• Cord cell banking sub-segment is poised to grow at the fastest CAGR, during the forecast period owing to the rise in the number of cord blood banking services across the globe
• By phase, the bank storage segment held a larger share of the global market. Technologically advanced cryopreservation techniques are expected to fuel the growth of this market throughout the forecast period
• Bank characterization & testing is expected to witness exponential growth opportunities. Bank characterization is an important quality-control procedure for cell-derived products
• North America held the largest share of the market, as there are a significantly high number of research and development projects ongoing in the region related to cytological investigation for proteomics, genomics, and drug and vaccine development. Growing need for vaccines and biopharmaceuticals is also anticipated to fuel the growth
• Asia Pacific is expected to witness significant growth in demand during the forecast period owing to an increase in the number of supportive government initiatives pertaining to investments in biotechnology sector. Additionally, ongoing R&D activities for cancer treatment and fertility preservation facilitate the demand for banking services

Introduction of novel technologies for the collection, testing, and storage of cell lines are expected to boost the cell banking market during the forecast period. Automation in cord blood processing and storage are the key technologies that are expected to affect the growth of the market.

CellTrials.org found that global enrolments of new trials in advanced cell therapy were up almost 30% in the first quarter of 2020. Most of the rise can be associated with cell therapy efforts for treating COVID-19, and over half of those trials for COVID-19 employ umbilical cord MSCs. Hence, the pandemic has created a new market for those companies which are engaged in the manufacturing of MSCs products.

According to a report published by Pharma Intelligence UK Limited, 21 oncological drugs are expected to be launched in 2022. Moreover, these drugs will be used for the treatment of different metabolic disorders which would result in the increased entry of novel biosimilar drugs into the market during the forecast period. For instance, in 2022, Center for Drug Evaluation and Research (CDER), approved 15 new drugs and biological products. Cell lines are highly valuable assets for the production and testing of these biopharmaceuticals. Hence, the increasing number of R&D activities for biosimilar and biologic products is expected to increase demand for the good-quality cell lines, thereby, fueling the demand for banking services.

Monoclonal antibody industry is growing at a rapid pace, owing to the advantages associated with it such as treatment for a wide array of diseases including autoimmune diseases, cancer, and inflammatory diseases. The demand for monoclonal antibodies for the treatment of these diseases is expected to increase during the forecast period, due to the benefits offered by them, which exhibit high efficiency, high specificity, and comparatively lesser side effects.

The increasing number of monoclonal antibody-based viable therapies, as well as the introduction of various new modalities related to their clinical development, are expected to drive the growth of the monoclonal antibodies. A clone with the best properties is chosen and stored in a bank, allowing for the production of monoclonal antibodies to be repeated for a decade. Therefore, the increasing growth of monoclonal antibodies is expected to propel the demand for banking throughout the forecast period.

Human embryonic research poses a moral duty such as respecting the value of human life and preventing suffering. The harvesting of embryonic stem cells violates the duty of respect value for human life as it is a consequence of the destruction of human embryos. In addition, granting of intellectual property rights (IPR) to the product or material used in research and commercialization of such services are the major restraints in cell development. Ethical approval should be obtained before the storage of cell lines and tissues in biorepositories as the technology allows patients identification just from DNA; which may lead to the misuse of tissue for an illegal purpose or for proxy identification of diseases to claim insurance.

Report Scope of the Cell Banking Outsourcing Market

Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/6794

Type Insights

Master cell banking accounted for the largest share of revenue in 2021, as their preparation is a prerequisite for the production and usage of working cell banks. They are preserved for a significantly longer duration, which also attracts the application of high-grade cryopreservation methodologies and equipment thereby further expanding the revenue base for this segment.

Furthermore, master cell banks find applicability in various research and development perspectives for stem cell therapy and gene therapy. Rising incidences of autoimmune diseases and cancer that can be treated by the use of therapies in combination with regenerative medicine is a key factor expected to fuel the growth of this segment, during the forecast period.

Cell Type Insights

Stem cells segment dominated the market with a share of 55.4%in 2021. Stem cells are obtained from cord blood, embryonic, adult, dental, and IPS cells, while non-stem include somatic cells preserved for applications such as tissue engineering and IPS cell development. An increase in research and development activities associated with the applications of stem cells drives the segment growth. For instance, in February 2021, American CryoStem collaborated with BioTherapeutic Labs Corp for the research and development in stem cell.

Cord cell banking accounted significant market share with respect to revenue in 2021 and their large share can be attributed to the rise in the number of cord blood banks and banking services across the globe. Cord blood provides significant advantages, which include serving as a source of hematopoietic stem cells, donor convenience, minimized risk of graft versus host diseases, low risk of viral contamination and immediate availability.

Phase Insights

Based on phase, the market is segmented into bank storage, bank characterization and testing, and bank preparation. Of these, storage accounted for the largest share of revenue owing to sophisticated preservation needs which are essential for proper maintenance of either master or working banks. Additionally, technologically advanced cryopreservation techniques are expected to fuel the growth of this market throughout the forecast period.

Bank storage in cell banking encompasses the preservation of both master and working banking and their respective safety testing. Bank characterization & testing is expected to witness lucrative growth during the forecast period owing to the presence of market players that are involved in providing outsourcing services for bank characterization &testing to different hospitals and clinical research organizations. For instance, Creative Biogene offers a wide-ranging bank characterization service to the customers to safeguard the biosafety and control of biotechnological and biological products.

Regional Insights

North America dominated the market and accounted for the largest market share of 40.70%in 2021 owing to the presence of extensive R&D laboratories and rising incidences of metabolic disorders such as Parkinson’s, Alzheimer’s, and various other types of cancers, which can be treated by gene therapy. The steep rate of increase in the establishment of banking services, which is a sign of rapid change, also contributes to the organizational diversity in the North American healthcare system.

Asia Pacific is expected to grow at an exponential rate throughout the forecast period. This exponential CAGR is credited to the presence of pharmaceutical companies, which are focusing their priorities on the large and relatively untapped populations in Asia.

Low cost of clinical trials and high investments in biotechnology sector is expected to fuel the market growth of this regional market. In May 2022, International Conference on Stem Cell Research and Therapy was held in China, aiming to give a platform for academicians, researchers, industrial professionals to present their research and discuss developments, and advancements in stem cell. Such initiatives by private and government organizations to discuss and support stem cell research is anticipated to help the market grow in this region.

Some of the prominent players in the Cell Banking Outsourcing Market include:

• Bio Reliance
• Bio Outsource (Sartorious)
• BSL Bioservice
• Cryo-Cell International, Inc
• Charles River Laboratories
• Covance
• Global Stem Inc.
• Goodwin Biotechnology Inc.
• Lonza
• SGS Life Sciences

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cell Banking Outsourcing market

• Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Master Cell Banking
  • Working Cell Banking
  • Viral Cell Banking
• Cell Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Stem Cell
    • Cord Cell Banking
    • Embryonic Stem Cell Banking
    • Adult Stem Cell Banking
    • Dental Stem Cell Banking
    • IPS Stem Cell Banking
  • Non-stem Cell
• Phase Outlook (Revenue, USD Million, 2018 - 2030)
  • Bank Storage
    • Master Cell Bank Storage
    • Working Cell Bank Storage
    • Cell Storage Stability Testing
  • Bank Characterization & Testing
    • Safety Testing
      • Viral Cell Banks
      • Microbial Cell Banks
    • Gene Expression Testing
    • Karyology Testing
    • Gene Sequencing Testing
  • Bank Preparation
    • Master Cell Bank Preparation
    • Working Cell Bank Preparation

Report Objectives

• To define, describe, and forecast the global Cell Banking Outsourcing market based on product, technique, methodology, category, and region
• To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, growth opportunities, and challenges)
• To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
• To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
• To forecast the size of the market segments with respect to five main regions—North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East and Africa
• To profile the key market players and comprehensively analyze their market shares and core competencies2
• To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global Cell Banking Outsourcing market

For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6794

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333